ReViral (London) receives $55m funding to carry on development of powerful antiviral

It’s time for dramatic change for the recently-established London-based startup ReViral, which has announced it has received $55m funding to  carry on the development of its powerful antiviral RV521 and to start new clinical trials, following the Phase IIa trial successfully conducted on 66 patients with serious respiratory tract infections caused by respiratory syncytial virus (RSV). ReViral has been funded by a consortium comprising New Leaf Venture Partners and Novo Ventures (part of Novo Holdings A/S), with contribution by Perceptive Advisors. The two main funders, New Leaf Ventures and Novo Ventures, will be also granted two ReViral’s board seats. ReViral was founded in London in 2011 by a group of managers and scientists with specific expertise in antivirals.

(Source: ReViral)